Alcon Inc (ALC)

Mar 29, 2025

Alcon Stock Might Rise as Clareon Vivity IOL Secures CE Mark Approval - MSN

Mar 29, 2025

Mar 29, 2025

Stifel maintains Alcon stock Buy rating, $100 target By Investing.com - Investing.com Australia

Mar 29, 2025

Mar 28, 2025

Citi maintains Alcon stock Buy rating, CHF99.00 target By Investing.com - Investing.com South Africa

Mar 28, 2025

Mar 28, 2025

Mizuho lifts Alcon stock price target to $120, maintains Outperform By Investing.com - Investing.com Canada

Mar 28, 2025

Mar 28, 2025

Taxation With Representation: Norton Rose, Latham, Ashurst - Law360

Mar 28, 2025

Mar 28, 2025

Alcon stock price target raised to $110 at Needham - Investing.com India

Mar 28, 2025

Mar 28, 2025

Alcon (ALC) Soars 6.0%: Is Further Upside Left in the Stock? - Yahoo Finance

Mar 28, 2025

Mar 28, 2025

Mizuho lifts Alcon stock price target to $120, maintains Outperform - Investing.com

Mar 28, 2025

Mar 28, 2025

Jefferies raises Alcon stock price target to $115, maintains Buy - Investing.com India

Mar 28, 2025

Mar 28, 2025

Jefferies raises Alcon stock price target to $115, maintains Buy By Investing.com - Investing.com South Africa

Mar 28, 2025

Mar 28, 2025

Citi maintains Alcon stock Buy rating, CHF99.00 target - Investing.com India

Mar 28, 2025

Mar 28, 2025

Alcon (VTX:ALC) ascends 4.7% this week, taking five-year gains to 80% - Yahoo Finance

Mar 28, 2025

Mar 28, 2025

Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Cell Therapy for Corneal Endothelial Disease - Vision Monday

Mar 28, 2025

Mar 27, 2025

Alcon Inc’s Acquisition of LENSAR Inc - Global Legal Chronicle

Mar 27, 2025

Mar 27, 2025

Alcon's Future Looks Fruitful as New Innovation and Commercial Execution Spark Market Outperformance - Morningstar

Mar 27, 2025

Mar 27, 2025

All eyes on ophthalmic cell therapy space as Alcon takes majority stake in Aurion - FirstWord Pharma

Mar 27, 2025

Mar 27, 2025

Alcon buys majority stake in IPO-seeking cell therapy startup Aurion - BioPharma Dive

Mar 27, 2025

Mar 27, 2025

Alcon claims control of cell therapy firm Aurion - pharmaphorum

Mar 27, 2025

Mar 27, 2025

Alcon acquires majority interest in Aurion Biotech - Ophthalmology Times

Mar 27, 2025

Mar 27, 2025

Alcon secures majority stake in Aurion, deposes CEO - PharmaLive

Mar 27, 2025

Mar 27, 2025

Related Content: Alcon to Acquire LENSAR | Business | Mar 2025 - Photonics.com

Mar 27, 2025

Mar 27, 2025

Alcon to buy Lensar in deal worth up to $430M - The Business Journals

Mar 27, 2025

Mar 27, 2025

Alcon to Acquire LENSAR | Business | Mar 2025 - Photonics.com

Mar 27, 2025

Mar 27, 2025

Alcon upgraded at BofA Securities to Buy on earnings growth potential - MSN

Mar 27, 2025

Mar 27, 2025

Alcon acquires majority interest in Aurion Biotech to advance first-ever corneal cell therapy candidate - BSA bureau

Mar 27, 2025

Mar 26, 2025

Aurion CEO is out as Alcon takes majority stake in cell therapy startup - Endpoints News

Mar 26, 2025

Mar 26, 2025

Alcon acquires majority stake in Aurion Biotech By Investing.com - Investing.com South Africa

Mar 26, 2025

Mar 26, 2025

Alcon buys majority stake in Aurion Biotech (ALC:NYSE) - Seeking Alpha

Mar 26, 2025

Mar 26, 2025

Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease - Sharewise

Mar 26, 2025

Mar 26, 2025

Alcon acquires majority stake in Aurion Biotech - Investing.com

Mar 26, 2025

Mar 26, 2025

Alcon Acquires Majority Interest In Aurion Biotech, Inc. To Advance Innovative Cell Therapy For Corneal Endothelial Disease - Marketscreener.com

Mar 26, 2025

Mar 26, 2025

Alcon signs merger agreement to acquire Lensar - MSN

Mar 26, 2025

Mar 26, 2025

Stifel maintains Alcon stock Buy rating, $100 price target By Investing.com - Investing.com Australia

Mar 26, 2025

Mar 26, 2025

Stifel maintains Alcon stock Buy rating with $100 target By Investing.com - Investing.com Australia

Mar 26, 2025

Mar 25, 2025

Bernstein maintains Alcon Outperform rating, $110.50 target - Investing.com

Mar 25, 2025

Mar 25, 2025

Alcon lines up Lensar deal to expand laser cataract surgery options - Optics.org

Mar 25, 2025

Mar 25, 2025

Alcon Gets EU Nod for Clareon Vivity Intraocular Lens - MPO-mag

Mar 25, 2025

Mar 25, 2025

Bank of America Upgrades Alcon (ALC) Stock Rating Amid Growth Pr - GuruFocus.com

Mar 25, 2025

Mar 25, 2025

HSBC and BofA have differing views on Alcon ahead of product launches - TradingView

Mar 25, 2025

Mar 25, 2025

ALC Stock Rises Following the Merger Agreement With LENSAR - Yahoo Finance

Mar 25, 2025

Mar 25, 2025

Stifel maintains Alcon stock Buy rating, $100 price target - Investing.com India

Mar 25, 2025

Mar 25, 2025

BofA raises Alcon stock rating, boosts target to CHF96 By Investing.com - Investing.com South Africa

Mar 25, 2025

Mar 25, 2025

Alcon agrees to purchase LENSAR - Ophthalmology Times

Mar 25, 2025

Mar 25, 2025

BofA raises Alcon stock rating, boosts target to CHF96 - Investing.com India

Mar 25, 2025

Mar 25, 2025

Switzerland: Alcon agrees acquisition of Lensar for up to US$430m - Investors in Healthcare

Mar 25, 2025

Mar 25, 2025

Alcon Gets CE Mark for Clareon Vivity Intraocular Lens - Marketscreener.com

Mar 25, 2025

Mar 25, 2025

Alcon Inc. receives Investment Bank Analyst Rating Update By Investing.com - Investing.com Australia

Mar 25, 2025